IRIS
MARRONE, Aldo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.266
EU - Europa 4.144
AS - Asia 987
AF - Africa 9
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 9.421
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.241
IE - Irlanda 1.377
UA - Ucraina 687
GB - Regno Unito 560
IT - Italia 517
CN - Cina 471
DE - Germania 336
SG - Singapore 278
SE - Svezia 237
FI - Finlandia 177
TR - Turchia 170
GR - Grecia 127
FR - Francia 60
KR - Corea 32
BE - Belgio 22
CA - Canada 21
IN - India 12
CZ - Repubblica Ceca 11
NL - Olanda 10
RU - Federazione Russa 8
IR - Iran 7
EU - Europa 6
ID - Indonesia 6
EG - Egitto 5
RO - Romania 5
JP - Giappone 4
AR - Argentina 3
CH - Svizzera 3
HR - Croazia 3
MX - Messico 3
CL - Cile 2
PE - Perù 2
TW - Taiwan 2
UG - Uganda 2
VN - Vietnam 2
AM - Armenia 1
AT - Austria 1
BD - Bangladesh 1
BR - Brasile 1
BW - Botswana 1
HU - Ungheria 1
JM - Giamaica 1
LI - Liechtenstein 1
MA - Marocco 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
Totale 9.421
Salva come PNG Salva come JPEG
Città #
Dublin 1.371
Jacksonville 1.045
Chandler 730
New York 256
Princeton 210
Singapore 164
Roxbury 158
Woodbridge 139
Ann Arbor 126
Boardman 123
Cambridge 116
Bremen 112
Wilmington 104
Medford 100
Caserta 64
Jinan 57
Beijing 56
San Mateo 53
Shenyang 52
Nanjing 50
Ashburn 49
Des Moines 44
Mountain View 41
Naples 38
Düsseldorf 33
Seoul 32
Zhengzhou 29
Nanchang 25
Brussels 22
Napoli 22
Houston 21
Norwalk 19
Washington 19
Changsha 17
Haikou 17
Los Angeles 16
Guangzhou 15
Hangzhou 15
Hebei 15
Munich 15
Helsinki 14
Ningbo 14
Auburn Hills 13
Lanzhou 13
Tianjin 12
Taiyuan 11
Taizhou 11
Kunming 10
Ottawa 10
Seattle 10
Shanghai 9
Dearborn 8
Jiaxing 8
Marano Di Napoli 8
Amsterdam 7
Rome 7
Milan 6
London 5
Marigliano 5
Portici 5
Redwood City 5
Rossano 5
Zanjan 5
Andover 4
Atlanta 4
Brno 4
Cesa 4
Changchun 4
Hefei 4
Hyderabad 4
Lappeenranta 4
Padova 4
Sacramento 4
Toronto 4
Venice 4
Avellino 3
Elora 3
Frattamaggiore 3
Palermo 3
Paris 3
Perugia 3
San Francisco 3
San Giuseppe Vesuviano 3
Tokyo 3
Zurich 3
Athens 2
Aversa 2
Bari 2
Barlassina 2
Bergamo 2
Bologna 2
Bonea 2
Brdo 2
Bucharest 2
Casteldaccia 2
Cava de' Tirreni 2
Chennai 2
Elice 2
Fairfield 2
Florence 2
Totale 5.899
Salva come PNG Salva come JPEG
Nome #
Cannabinoid receptor 2-63 QQ varianti s associated with severe necroinflammation in chronic epatiti C 110
Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease 101
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 91
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 91
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms 85
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C 83
Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. 78
Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment 72
null 71
Effect of prednisone priming followed by alpha-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trial 70
IMPACT OF TYPE II DIABETES ON HCC APPEARANCE IN PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 70
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 69
The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. 68
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe. 68
PNPLA3 l148M variant as a risk factor for carotid atherosclerosis in chronic epatiti C 66
Espressione dell'infezione da citomegalovirus (CMV) in pazienti cardiotrapiantati 66
Chronic HCV infection and neurological and psychiatric disorders: an overview. 65
Pleurite da Listeria monocytogenes in un paziente con cirrosi epatica: osservazione di un caso clinico 63
Le complicanze infettive in pazienti sottoposti a trapianto di cuore: dati del centro napoletano. 63
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B 62
Long term effect of interferon (IFN) treatment of chronic hepatitis B (CHB) in pediatric patients cured of oncologic diseases 62
Activity of aminoglycosides against phagocytosed bacteria 61
Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali 61
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. 61
Cannabinoid Receptor 2 (CB2) Q63 variant in chronic hepatitis C: an association with a more severe hepatocellular necrosis. 60
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B. 60
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection 59
Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B 58
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon 58
Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study 58
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 58
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B 58
Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study 57
Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection 57
Ricerca del sangue occulto nelle feci con Hemoquant: prevenzione e diagnostica. 57
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 57
Eighteen months lamivudine prophylaxis of occult HBV infection (OBI) reactivation and standard therapy of overt chronic infection in oncohematologic immunosuppressed patients: an interim analysis 57
Complicanze infettive in pazienti sottoposti a trapianto di cuore. 57
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 56
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. 56
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe 56
Cannabinoid receptor 2 (CB2) Q63 variant is associated with a severe histological activity index in patients with chronic hepatitis C 56
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore. 56
CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. 56
Effects of long-term alfa interferon treatment in 344 patients with chronic hepatitis C: retrospective analysis of dosage and type of interferon used 55
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 55
Absence of hepatitis C viral infection among patients with primary Sjogren's syndrome 55
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B 55
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 55
Hepatitis C virus infection in Italy: a multicentric sero-epidemiological study. (A report from the HCV study group of the Italian Association for the study of the liver) 54
Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission 54
Interferon plus lamivudine treatment in young patients with chronic active B and C hepatitis 54
Severe diarrhea occurring during alpha-interferon treatment for chronic hepatitis C is associated with serologic markers of celiac disease 54
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 53
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C 53
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. 53
EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV 53
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis 52
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 52
Chronic hepatitis B infection in pediatric patients cured of oncologic diseases: natural history and effect of interferon treatment 52
Correlation of serum HBeAg levels and double A1762T/G1764A HBV core promoter mutation with response to interferon in patients with chronic hepatitis B 52
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici. Nostra esperienza negli ultimi 4 anni. 51
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 51
Suscettibilità antibiotica di enterococchi recentemente isolati. 51
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 51
Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology? 50
Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays 50
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients 50
SEQUENTIAL ANALYSIS OF HEPATITIS B VIRUS CORE PROMOTER AND PRECORE REGIONS IN CANCER SURVIVOR PATIENTS WITH CHRONIC HEPATITIS B BEFORE, DURING AND AFTER INTERFERON TREATMENT 50
Genetic heterogeneity of hepatitis C virus. The clinical significance of genotypes and quasispecies behavior 50
HCV-related steatosis and risk of atherosclerosis 50
La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico. 50
Efficacia del trattamento con interferone ricombinante e linfoblastoide in pazienti con epatite cronica da HCV. 50
Chronic HCV infection is a risk factor of ischemic stroke 50
Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant 50
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy 50
Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays 49
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia 49
Tm6sf2 e167k variant is associated with severe steatosis in chronic hepatitis c, regardless of pnapl3 polymorphism 49
Baseline HBV-DNA level is an important predictor of response to interferon in children with chronic hepatitis B 49
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore 49
Infezioni respiratorie da Branhamella Catarralis in pazienti sottoposti a trapianto di cuore 49
Efficacia e tollerabilità dell'alfa interferone (IFN) nell'epatite cronica post-trasfusionale (PTCH) da HCV: dati preliminari di soggetti precedentemente sottoposti a cardiochirurgia. 49
Clearance of HBsAg and HBV-DNA after lamivudine (LAM) or entecavir (ET) rescue therapy in oncohaematological patients with hepatitis B virus (HBV) reactivation: complete recovery of four cases 49
ESPERIENZA CON L'INTERFERONE LINFOBLASTOIDE NELLE EPATITI CRONICHE VIRALI 49
COVID-19 and arrhythmia: The factors associated and the role of myocardial electrical impulse propagation. An observational study based on cardiac telemetric monitoring 48
Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study 48
The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology 48
Aspetti diagnostici di mutanti della regione HBsAg in pazienti immunocompromessi con riattivazione dell’infezione da virus dell’epatite B (HBV). 48
Studio prospettico controllato del trattamento prednisone interferone in pazienti pediatrici con epatite cronica da HBV 48
The TM6SFZ 8167K variant is an independent predictor of severe liver steatosis in chronic hepatitis C 48
Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection 47
Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection 47
Studio dellla suscettibilità antibiotica di stafilococchi responsabili di infezioni nosocomiali 47
The epidemiology of hepatitis delta infection in Italy 46
Efficacia e sicurezza dell’entecavir nel controllo dell’infezione da HBV nel paziente oncoematologico 46
Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals 46
Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment. Predictive Factors and Role of Epigenetics 46
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. 45
Hepatic steatosis and necro-inflammatory activity overestimated liver stiffness by transient elastography in staging liver fibrosis in chronic hepatitis C 45
Totale 5.713
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.067
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.067
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020667 0 0 0 7 193 34 229 39 59 32 62 12
2020/20211.682 120 15 173 95 435 16 205 159 8 214 175 67
2021/20221.285 59 3 8 15 435 14 11 35 64 124 103 414
2022/20232.729 235 47 40 222 332 226 4 177 1.295 27 64 60
2023/20241.212 96 33 61 97 373 262 17 35 4 14 77 143
2024/2025168 27 42 34 65 0 0 0 0 0 0 0 0
Totale 9.803